PLOS ONE: A single-arm, open-label, phase 2 clinical trial evaluating disease response following treatment with BI-505, a human anti-intercellular adhesion molecule-1 monoclonal antibody, in patients with smoldering multiple myeloma
3 month randomised double blind, placebo-controlled phase followed by a 24-month open-label, single-arm phase. The primary endpoint of the trial was to compare the efficiency (4) - Debra Ireland
New approaches to clinical trials: Adaptive designs - EUPATI Toolbox
Biology | Free Full-Text | Bright Light Therapy for Parkinson Disease: A Literature Review and Meta-Analysis of Randomized Controlled Trials | HTML
Evaluation of apremilast in chronic pruritus of unknown origin: A proof‐of‐concept, phase 2a, open‐label, single‐arm clinical trial - Clark - 2020 - Health Science Reports - Wiley Online Library
Hanan Goldberg on Twitter: "Dr. De Wit presenting Keynote 057 study results, a single arm open label study of pembrolizumab in NMIBC patients unresponsive to BCG, demonstrating complete response rates of 38.8%!
![PDF] An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer: Interim results. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/bd292c301c51a1f717d8f0c14788762c69120a87/4-Figure1-1.png "PDF] An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer: Interim results. | Semantic Scholar")
PDF] An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer: Interim results. | Semantic Scholar
Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study - The Lancet Respiratory Medicine
An Open-label, Single-arm Study of CRYO2 for Debulking at the Site of Central Airway Obstruction or Stenosis | In Vivo
![PDF] A single-arm, open-label study to assess the immunogenicity, safety, and efficacy of etanercept manufactured using the serum-free, high-capacity manufacturing process administered to patients with rheumatoid arthritis | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/ff8c21a61028240726f6a4d4b51edb39ea052f1c/3-Figure1-1.png "PDF] A single-arm, open-label study to assess the immunogenicity, safety, and efficacy of etanercept manufactured using the serum-free, high-capacity manufacturing process administered to patients with rheumatoid arthritis | Semantic Scholar")
PDF] A single-arm, open-label study to assess the immunogenicity, safety, and efficacy of etanercept manufactured using the serum-free, high-capacity manufacturing process administered to patients with rheumatoid arthritis | Semantic Scholar
CONSORT flowchart for A single-arm, open-label, phase 2 clinical trial... | Download Scientific Diagram
A Phase III, Open-Label, Single-Arm Study of Tenecteplase for Restoration of Function in Dysfunctional Central Venous Catheters - Journal of Vascular and Interventional Radiology
Rationale and study design of MOTION: A phase 4, prospective, single-arm, open-label study to measure outcomes in patients with pulmonary arterial hypertension not on active treatment - Respiratory Medicine
Study 079 An OpenLabel SingleArm Phase 2 Trial
Effect of Facial Cosmetic Acupuncture on Facial Elasticity: An Open-Label, Single-Arm Pilot Study – topic of research paper in Clinical medicine. Download scholarly article PDF and read for free on CyberLeninka open
Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial - The Lancet Oncology
SOF + PEG-IFN ï -2a + RBV Open-label Single arm ≥ 18 years Chronic HCV infection Genotype 1, 4, 5 or 6 Treatment-na¯ve HCV RNA ≥ 10,000 IU/ml Compensated
ASCO GU 2021: SURE: An Open Label, Sequential-Arm, Phase II Study of Neoadjuvant Sacituzumab Govitecan, and Sacituzumab Govitecan plus Pembro Before Radical Cystectomy, for Patients with MIBC Who Cannot Receive or Refuse
PLOS ONE: A single-arm, open-label, phase 2 clinical trial evaluating disease response following treatment with BI-505, a human anti-intercellular adhesion molecule-1 monoclonal antibody, in patients with smoldering multiple myeloma
Neutropenia Prevention in the Treatment of Post-docetaxel Metastatic, Castration-resistant Prostate Cancer With Cabazitaxel and Prednisone: A Multicenter, Open-label, Single-arm Phase IV Study - Clinical Genitourinary Cancer
Statistical controversies in clinical research: limitations of open-label studies assessing antiangiogenic therapies with regard to evaluation of vascular adverse drug events—a meta-analysis - ScienceDirect
The study was design as single-arm open-label trial consisting of a 14... | Download Scientific Diagram
